Bank of New York Mellon Corp - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 92 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$1,461,124
-19.8%
120,954
+8.0%
0.00%
Q1 2024$1,820,794
+122.5%
111,980
-6.7%
0.00%
Q4 2023$818,175
+25.5%
119,967
+0.3%
0.00%
Q3 2023$651,848
-18.8%
119,605
+1.1%
0.00%
Q2 2023$803,162
+42.5%
118,286
+5.1%
0.00%
Q1 2023$563,780
+1.9%
112,531
-0.7%
0.00%
Q4 2022$553,099
-66.2%
113,340
-0.0%
0.00%
Q3 2022$1,634,000
+5.2%
113,355
+10.4%
0.00%
Q2 2022$1,553,000
+25.4%
102,657
-1.4%
0.00%
Q1 2022$1,238,000
-26.1%
104,135
+0.8%
0.00%
Q4 2021$1,675,000
-43.4%
103,345
-0.3%
0.00%
-100.0%
Q3 2021$2,958,000
-4.5%
103,634
+13.1%
0.00%0.0%
Q2 2021$3,097,000
+1.5%
91,626
-9.2%
0.00%0.0%
Q1 2021$3,051,000
-42.8%
100,910
-6.4%
0.00%0.0%
Q4 2020$5,335,000
+32.2%
107,759
+2.5%
0.00%0.0%
Q3 2020$4,035,000
-10.7%
105,109
+0.5%
0.00%0.0%
Q2 2020$4,519,000
+102.6%
104,603
+22.4%
0.00%0.0%
Q1 2020$2,231,000
-14.8%
85,463
+1.9%
0.00%0.0%
Q4 2019$2,620,000
+70.5%
83,832
+42.1%
0.00%
Q3 2019$1,537,000
+16.3%
59,001
+2.0%
0.00%
Q2 2019$1,322,000
+149.4%
57,829
+186.0%
0.00%
Q1 2019$530,00020,2200.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Sofinnova Investments, Inc. 2,194,278$84,238,0006.25%
Burrage Capital Management LLC 123,025$4,723,0003.73%
MPM BioImpact LLC 337,291$12,949,0003.12%
First Light Asset Management, LLC 608,193$23,349,0002.39%
Cormorant Asset Management, LP 1,397,700$53,658,0002.06%
SPHERA FUNDS MANAGEMENT LTD. 396,521$15,222,0001.50%
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. 801$33,0000.61%
Artal Group S.A. 285,028$10,942,0000.27%
DRIEHAUS CAPITAL MANAGEMENT LLC 298,213$11,448,0000.24%
Virtus ETF Advisers LLC 7,309$281,0000.15%
View complete list of Y-MABS THERAPEUTICS INC shareholders